What is claimed is:

1. A method of ~~preventing or~~ reducing formation of fatty acid particles in a formulation capable of forming fatty acid particles, comprising:

(a) obtaining a formulation comprising an active pharmaceutical agent, a polysorbate, and at least one lipase, wherein said formulation is capable of forming fatty acid particles; and

(b) adding to the formulation an effective amount of human serum albumin.

~~2. The method of claim 1, wherein the formulation comprises a polysorbate.~~

2~~3~~. The method of claim 1, wherein the formulation comprises one or more additional proteins.

3~~4~~. The method of claim 1, wherein the fatty acid particles comprise a free fatty acid.

4~~5~~. The method of claim 1, wherein the fatty acid particles comprise a free fatty acid selected from the group consisting of oleic acid, palmitic acid, stearic acid, myristic acid, lauric acid, and combinations thereof.

5~~6~~. The method of claim 1, wherein concentration of the human serum albumin in the formulation is at least ~~about~~ 5.5 mg/mL.

~~7~~6. The method of claim 1, wherein the method ~~reduces~~ is capable of reducing formation of fatty acid particles comprising a free fatty acid with ~~about~~ from six to ~~about twenty~~ twenty-two carbon atoms.

~~8~~7. The method of claim 1, wherein the formulation is a parenteral formulation.

~~9~~8. The method of claim 1, wherein the method is capable of reducing~~reduces~~ fatty acid particles that form visible or sub-visible particles.

~~10~~9. The method of claim 1, wherein an effective amount of human serum albumin includes one mole of ~~the~~ human serum albumin binding~~s~~ to at least a half mole of a free fatty acid contained in the fatty acid particles.

~~11~~10. The method of claim 1, wherein the method is capable of reducing the formation of fatty acid particles ~~are~~ at least 10 µm in size.

~~12~~11. The method of claim 1, further comprising using ~~wherein the fatty acid particles are detected by~~ Raman spectroscopy to detect the fatty acid particles.

~~13~~12. The method of claim ~~1~~2, wherein the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, and a combination thereof.

~~14~~13. The method of claim ~~2~~1, wherein the concentration of the polysorbate in the formulation is from ~~about~~ 0.001 % w/v to ~~about~~ 1% w/v.

~~15~~14. The method of claim ~~3~~2, wherein the additional protein is an antibody.

~~16~~15. The method of claim ~~3~~2, wherein the additional protein is a monoclonal antibody.

~~17~~16. The method of claim ~~3~~2, wherein the additional protein is a polyclonal antibody.

~~18~~17. The method of claim ~~of claim~~ ~~5~~3, wherein a ratio of molecules of the free fatty acid to molecules of the human serum albumin in the formulation is ~~about~~ from 6:1 to ~~about~~ 1:1.

~~19~~18. A method of solubilizing fatty acid particles formed in a formulation, comprising:

(a) obtaining a formulation comprising an active pharmaceutical agent, a polysorbate, and at least one lipase, wherein said formulation is capable of forming fatty acid particles; and

(b) adding to the formulation an effective amount of human serum albumin.

~~20~~19. A formulation, comprising:

an active pharmaceutical agent,

a polysorbate,

at least one lipase, and

at least 5.5 mg/mL human serum albumin,

wherein said formulation is capable of forming fatty acid particles, and wherein said active pharmaceutical agent is not human serum albumin.

~~21~~20. The ~~protein~~ formulation of claim ~~20~~19, wherein the active pharmaceutical agent comprises a monoclonal antibody.

~~22~~21. The ~~protein~~ formulation of claim ~~20~~19, wherein the active pharmaceutical agent comprises a polyclonal antibody.

~~23~~22. The ~~protein~~ formulation of claim ~~20~~19, wherein the active pharmaceutical agent comprises a therapeutic antibody.

~~24~~23. The ~~protein~~ formulation of claim ~~20~~19, wherein the polysorbate is selected from the group consisting of polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, or a combination thereof.

~~25. The protein formulation of claim 20, wherein the formulation further comprises a lipase enzyme.~~

~~26. The protein formulation of claim 20, wherein concentration of the human serum albumin in the protein formulation is at least about 5.5 mg/mL.~~

~~27~~24. The ~~protein~~ formulation of claim ~~20~~19, wherein the formulation is a parenteral formulation.

~~28~~25. The ~~protein~~ formulation of claim ~~20~~19, wherein the ~~polysorbate degrades to form~~ fatty acid particles are formed by degradation of the polysorbate.

~~29~~26. The ~~protein~~ formulation of claim ~~28~~25, wherein the fatty acid particles comprise a free fatty acid.

~~30~~27. The ~~protein~~ formulation of claim ~~29~~26, wherein the free fatty acid is an aliphatic acid with ~~about~~ from six to ~~about twenty~~ twenty-two carbons.

~~31~~28. The ~~protein~~ formulation of claim ~~29~~26, wherein the free fatty acid is oleic acid.

~~32~~29. The ~~protein~~ formulation of claim ~~29~~26, wherein the free fatty acid is selected from the group consisting of oleic acid, palmitic acid, stearic acid, myristic acid, lauric acid, and combinations thereof.

~~33~~30. The ~~protein~~ formulation of claim ~~29~~26, wherein a ratio of molecules of the free fatty acid to molecules of the human serum albumin in the formulation is ~~about~~ from 6:1 to ~~about~~ 1:1.

~~34~~31. The ~~protein~~ formulation of claim ~~20~~19, wherein the concentration of the polysorbate in the ~~protein~~ formulation is from ~~about~~ 0.001% w/v to 1% w/v.

32. The formulation of claim 19, wherein the human serum albumin is fatty acid-free human serum albumin.